Table 1 Baseline characteristics of participants.
From: Influential factors and predictive model of anemia in hospitalized elderly patients
Characteristics | Total (N = 864) | Non-anemia (n = 546) | Anemia (n = 318) | P-value |
|---|---|---|---|---|
Age | 76.3 ± 10.3 | 73.7 ± 10.2 | 80.9 ± 8.9 | < 0.001 |
Sex | 0.683 | |||
 Male | 448 (51.9) | 286 (52.4) | 162 (50.9) |  |
 Female | 416 (48.1) | 260 (47.6) | 156 (49.1) |  |
Comorbidities | ||||
 Hypertension | 314 (36.3) | 172 (31.5) | 142 (44.7) | < 0.001 |
 CAD | 382 (44.2) | 186 (34.1) | 196 (61.6) | < 0.001 |
 HF | 182 (21.1) | 76 (13.9) | 106 (33.3) | < 0.001 |
 CVD | 334 (38.7) | 202 (37) | 132 (41.5) | 1.726 |
 NDD | 222 (25.7) | 118 (21.6) | 104 (32.7) | < 0.001 |
 Diabetes | 426 (49.3) | 286 (52.4) | 140 (44) | 0.018 |
 KD | 52 ( 6.0) | 22 (4) | 30 (9.4) | 0.001 |
 Infectious diseases | 390 (45.1) | 190 (34.8) | 200 (62.9) | < 0.001 |
 Cancer | 76 ( 8.8) | 36 (6.6) | 40 (12.6) | 0.003 |
Laboratory tests | ||||
 HGB (g/L) | 119.6 ± 21.1 | 132.5 ± 14.4 | 97.6 ± 9.3 | < 0.001 |
 WBC (×109) | 8.2 ± 4.0 | 8.0 ± 3.7 | 8.6 ± 4.4 | 0.026 |
 PLT (×109) | 234.9 ± 88.5 | 237.2 ± 78.4 | 230.9 ± 103.6 | 0.314 |
 CRP (mg/L) | 16.2 (4.2, 60.4) | 8.4 (2.8, 39.5) | 36.9 (11.2, 93.7) | < 0.001 |
 PCT (ng/ml) | 0.1 (0.0, 0.3) | 0.0 (0.0, 0.2) | 0.1 (0.0, 0.7) | < 0.001 |
 ALT (U/L) | 14.0 (9.0, 22.0) | 15.0 (10.0, 23.0) | 13.0 (9.0, 22.0) | 0.015 |
 AST (U/L) | 17.0 (13.0, 23.0) | 17.0 (13.0, 22.0) | 18.0 (13.2, 24.0) | 0.630 |
 GGT (U/L) | 19.0 (13.0, 32.5) | 19.0 (13.0, 30.0) | 19.0 (13.0, 37.8) | 0.737 |
 TBIL (umol/L) | 8.5 (6.1, 12.1) | 8.6 (6.1, 12.2) | 8.0 (6.0, 12.1) | 0.114 |
 ALB (g/L) | 35.9 ± 6.6 | 38.1 ± 6.0 | 32.1 ± 5.8 | < 0.001 |
 Cr (umol/L) | 61.0 (49.0, 76.0) | 63.0 (52.0, 75.0) | 55.0 (43.0, 80.0) | 0.001 |
 Ur (mmol/L) | 5.2 (4.1, 8.0) | 5.2 (4.1, 7.1) | 5.3 (4.1, 8.8) | 0.063 |
 UA (umol/L) | 283.3 ± 132.2 | 285.3 ± 121.1 | 279.8 ± 149.6 | 0.559 |
 PT (s) | 13.7 ± 2.7 | 13.5 ± 2.6 | 13.8 ± 2.8 | 0.108 |
 APTT (s) | 37.6 ± 6.2 | 36.9 ± 5.6 | 38.7 ± 7.1 | < 0.001 |
 D-Dimer (ug/ml) | 2.2 ± 1.6 | 2.0 ± 1.5 | 2.4 ± 1.6 | < 0.001 |
 K (mmol/L) | 4.1 ± 0.6 | 4.1 ± 0.4 | 4.0 ± 0.9 | 0.208 |
 Na (mmol/L) | 136.9 ± 8.4 | 137.7 ± 9.2 | 135.4 ± 6.4 | < 0.001 |
 CL (mmol/L) | 100.9 ± 5.8 | 102.0 ± 5.4 | 99.1 ± 6.0 | < 0.001 |
 Ca (mmol/L) | 2.1 ± 0.2 | 2.1 ± 0.2 | 2.0 ± 0.2 | < 0.001 |
 Mg (mmol/L) | 0.9 ± 0.1 | 0.8 ± 0.1 | 0.9 ± 0.1 | 0.677 |
 P (mmol/L) | 1.2 ± 0.8 | 1.2 ± 0.8 | 1.1 ± 0.8 | 0.177 |
 NT-proBNP (pg/ml) | 393.1 (102.8, 1490.5) | 282.4 (68.6, 1119.0) | 806.1 (190.6, 2801.2) | < 0.001 |
 25(OH)D (nmol/L) | 54.8 ± 24.8 | 66.9 ± 21.7 | 34.0 ± 13.2 | < 0.001 |
 MDR | 258 (29.9) | 136 (24.9) | 122 (38.4) | < 0.001 |
Diet and treatment | ||||
 VD intake | 50 ( 5.8) | 38 (7) | 12 (3.8) | 0.053 |
 Probiotic intake | 152 (17.6) | 90 (16.5) | 62 (19.5) | 0.262 |
Iron supplementation | < 0.001 | |||
 Oral | 132 (15.3) | 72 (13.2) | 60 (18.9) |  |
 Intravenous | 192 (22.2) | 88 (16.1) | 104 (32.7) |  |
 Application of EPO | 80 ( 9.3) | 34 (6.2) | 46 (14.5) | < 0.001 |
